James Dahlman

Associate Professor

Emory University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Tissue Engineering Tissue Engineering professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

James Dahlman is an Associate Professor at Emory University School of Medicine, located in the United States. His research focuses on the development of advanced drug delivery systems, particularly those involving mRNA and lipid nanoparticles, for applications in treating genetic disorders and cancers. Recent publications include work on microneedle patches for mRNA delivery and allele-selective silencing technologies for von Willebrand disease.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Feng Zhang

Harvard University

UNITED STATES

View details

Cecile Denis

INSERM

FRANCE

View details

Alejandro Da Silva Sanchez

UNITED STATES

View details

Ruben Bierings

NETHERLANDS

View details

Hyejin Kim

Assistant Professor

Emory University

UNITED STATES

View details

Eric J. Sorscher

Emory University School of Medicine

UNITED STATES

View details

Frank Leebeek

Erasmus University Rotterdam

NETHERLANDS

View details

Mark R. Prausnitz

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James Dahlman

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Development of a microneedle patch for delivery of mRNA-lipid nanoparticles

Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs

The time course of in vivo cellular responses to LNPs

Nucleic acid-based drugs for patients with solid tumours

Substituting Poly(ethylene glycol) Lipids with Poly(2-ethyl-2-oxazoline) Lipids Improves Lipid Nanoparticle Repeat Dosing.

Drug delivery systems for CRISPR-based genome editors

Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo

The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure

Universal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery

Non-liver mRNA Delivery

Dataset of bond enthalpies (εAA, εAB, εBB) in 975 binary intermetallic compounds

Therapeutic RNA Delivery for COVID and Other Diseases

Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands

Increased PIP3 activity blocks nanoparticle mRNA delivery

Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery

Collaborators (8)

Feng Zhang

Cecile Denis

Alejandro Da Silva Sanchez

Ruben Bierings

Hyejin Kim

Eric J. Sorscher

Frank Leebeek

Mark R. Prausnitz

Make your next move.